CERO · Cero Therapeutics Holdings, Inc. · Debt
$0.07
-0.02 (-25.26%)
At close · Oct 31
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$716,309
Shares
71.63M
Volume · Oct 31
7.27M
Avg daily vol (3M)
2.14M
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2026-06-30 | USD 14,793 | 10-Q filed 2026-08-14 |
| Current portion of convertible debt | 2026-06-30 | USD 746,647 | 10-Q filed 2026-08-14 |
| Current portion of convertible notes payable | 2026-06-30 | USD 746,647 | 10-Q filed 2026-08-14 |
| Operating lease liabilities | 2026-06-30 | USD 218,308 | 10-Q filed 2026-08-14 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.